Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

(2021) Madhumita Shrotri et al.   LANCET

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

(2021) ShengLi Xia et al.   LANCET INFECTIOUS DISEASES

COVID vaccines slash viral spread – but Delta is an unknown

(2021) Smriti Mallapaty   NATURE

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

(2021) Victoria G. Hall et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

(2021) Ann R. Falsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

(2021) Yinon M. Bar-On et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

(2021) David Hillus et al.   Lancet Respiratory Medicine

Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19

(2021) Yun Tan et al.   Cell Discovery

Evolution of the SARS-CoV-2 genome and emergence of variants of concern

(2021) Iman Safari et al.   ARCHIVES OF VIROLOGY

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine

(2021) Yunlong Cao et al.   CELL RESEARCH

Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern

(2021) Jingwen Ai et al.   CELL RESEARCH

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

(2021) Gang Zeng et al.   LANCET INFECTIOUS DISEASES

Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia

(2021) Cristina Bagacean et al.   Blood Advances

Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury

(2020) Yingxia Liu et al.   National Science Review

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

(2020) Shengli Xia et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

I3: A Self-organising Learning Workflow for Intuitive Integrative Interpretation of Complex Genetic Data

(2019) Yun Tan et al.   GENOMICS PROTEOMICS & BIOINFORMATICS

Complex heatmaps reveal patterns and correlations in multidimensional genomic data

(2016) Zuguang Gu et al.   BIOINFORMATICS

supraHex: An R/Bioconductor package for tabular omics data analysis using a supra-hexagonal map

(2013) Hai Fang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS